Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Paul Chan & Christopher Wai Kei Lam. (2022) The role of sulfonylureas in the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 23:3, pages 387-403.
Read now
Read now
Nesreen Aldawi, Gassan Darwiche, Salah Abusnana, Murtada Elbagir & Targ Elgzyri. (2019) Initial increase in glucose variability during Ramadan fasting in non-insulin-treated patients with diabetes type 2 using continuous glucose monitoring. Libyan Journal of Medicine 14:1.
Read now
Read now
Awadhesh Kumar Singh & Ritu Singh. (2016) Is gliclazide a sulfonylurea with difference? A review in 2016. Expert Review of Clinical Pharmacology 9:6, pages 839-851.
Read now
Read now
Kamran MA Aziz. (2015) Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients. Diabetes, Metabolic Syndrome and Obesity 8, pages 207-211.
Read now
Read now
Mohamed Hassanein, Khalifa Abdallah & Anja Schweizer. (2014) A double-blind, randomized trial, including frequent patient–physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vascular Health and Risk Management 10, pages 319-326.
Read now
Read now
Anja Schweizer, Serge Halimi & Sylvie Dejager. (2014) Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan. Vascular Health and Risk Management 10, pages 15-24.
Read now
Read now
Sosale R. Aravind. (2014) Adding a DPP-4 inhibitor to metformin therapy may be safer than you think. Current Medical Research and Opinion 30:5, pages 791-794.
Read now
Read now
A.H. Barnett, R. Brice, W. Hanif, J. James & H. Langerman. (2013) Increasing awareness of hypoglycaemia in patients with Type 2 diabetes treated with oral agents. Current Medical Research and Opinion 29:11, pages 1503-1513.
Read now
Read now
Articles from other publishers (46)
Shaun Wen Huey Lee, Won Sun Chen, Renukha Sellappans, Shakirah Binti Md.Sharif, Maria-Inti Metzendorf & Nai Ming Lai. (2023) Interventions for people with type 2 diabetes mellitus fasting during Ramadan. Cochrane Database of Systematic Reviews 2023:7.
Crossref
Crossref
Yousef Al Saleh, Noor Al Busaidi, Waleed Al Dahi, Munawar Almajnoni, Al Saeed Mohammed, Khalid Alshali, Mostafa Al-Shamiri, Saud Al Sifri, Mohammed Arafah, Siew Pheng Chan, Hassan El-Tamimi, Khadija Hafidh, Mohamed Hassanein, Ashraf Shaaban, Ali Sultan & Guido Grassi. (2023) Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit. Advances in Therapy 40:7, pages 2965-2984.
Crossref
Crossref
Mohamed Hassanein, Mousa A. J. Akbar, Mostafa Al-shamiri, Ashraf Amir, Aslam Amod, Richard Chudleigh, Tarik Elhadd, Hussien Heshmat, Mahdi Jibani & Yousef M. Al Saleh. (2022) Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies. Diabetes Therapy 13:7, pages 1253-1280.
Crossref
Crossref
Syed Abbas Raza, Javed Akram, Azizul Hasan Aamir, Yakoob Ahmedani & Mohammad Imtiaz Hassan. (2021) Evaluation of the effectiveness and tolerability of gliclazide modified release 60 mg in patients with type 2 diabetes observing fasting during Ramadan in Pakistan: An analysis from the global DIA-RAMADAN study. Diabetes Research and Clinical Practice 181, pages 109086.
Crossref
Crossref
Subhash Wangnoo, M. Shunmugavelu, Sagili Vijaya Bhaskar Reddy, Vijay Negalur, Shreerang Godbole, Vinay K Dhandhania, Nareen Krishna & Kumar Gaurav. (2021) Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India. Endocrine and Metabolic Science 4, pages 100102.
Crossref
Crossref
Yousef Al-Saleh, Shaun Sabico, Ahmed Al-Furqani, Amin Jayyousi, Dalal Alromaihi, Ebtesam Ba-Essa, Fatheya Alawadi, Juma Alkaabi, Mohamed Hassanein, Saud Al-Sifri, Seham Saleh, Thamer Alessa & Nasser M. Al-Daghri. (2021) Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas. Diabetes Therapy 12:8, pages 2115-2132.
Crossref
Crossref
Mohamed Hassanein, Saud Al Sifri, Shehla Shaikh, Syed Abbas Raza, Javed Akram, Achmad Rudijanto, Inass Shaltout, Md. Fariduddin, Wan Mohd Izani Bin Wan Mohamed, Fatheya Al Awadi, Alexandra Durocher, Viviana Cortese & Thamer Alessa. (2021) Descriptive Regional Subanalysis of a Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide MR During Fasting: DIA-RAMADAN. Diabetes Therapy 12:6, pages 1703-1719.
Crossref
Crossref
Dana Abdelrahim, MoezAlIslam E. Faris, Mohamed Hassanein, Ayman Z. Shakir, Ayesha M. Yusuf, Aljohara S. Almeneessier & Ahmed S. BaHammam. (2021) Impact of Ramadan Diurnal Intermittent Fasting on Hypoglycemic Events in Patients With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials and Observational Studies. Frontiers in Endocrinology 12.
Crossref
Crossref
Tarik Elhadd, Mohamed Bashir, Khaled A. Baager, Hamda A. Ali, Dabia H.S. Almohannadi, Zainab Dabbous, Rayaz A. Malik & Abdul-Badie Abou-Samra. (2021) Mitigation of hypoglycemia during Ramadan using the flash glucose monitoring system following dose adjustment of insulin and sulphonylurea in patients taking multiple glucose-lowering therapies (The PROFAST-IT Study). Diabetes Research and Clinical Practice 172, pages 108589.
Crossref
Crossref
Syed H. Ahmed, Tahseen A. Chowdhury, Sufyan Hussain, Ateeq Syed, Ali Karamat, Ahmed Helmy, Salman Waqar, Samina Ali, Ammarah Dabhad, Susan T. Seal, Anna Hodgkinson, Shazli Azmi & Nazim Ghouri. (2020) Ramadan and Diabetes: A Narrative Review and Practice Update. Diabetes Therapy 11:11, pages 2477-2520.
Crossref
Crossref
Kamlesh Khunti, Mohamed Hassanein, Moon-Kyu Lee, Viswanathan Mohan & Aslam Amod. (2020) Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. Diabetes Therapy 11:S2, pages 33-48.
Crossref
Crossref
W. Hanif, V. Patel, S.N. Ali, A. Karamat, M. Saeed, M. Hassanein, A. Syed, T.A. Chowdhury, A. Farooqi & K. Khunti. (2020) The South Asian Health Foundation (UK) guidelines for managing diabetes during Ramadan. Diabetes Research and Clinical Practice 164, pages 108145.
Crossref
Crossref
Mohamed Hassanein, Saud Al Sifri, Shehla Shaikh, Syed Abbas Raza, Javed Akram, Agung Pranoto, Achmad Rudijanto, Inass Shaltout, Md Fariduddin, Wan Mohd Izani Wan Mohamed, Fatheya Al Awadi & Thamer Alessa. (2020) A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Research and Clinical Practice 163, pages 108154.
Crossref
Crossref
David Morris. (2020) Managing diabetes in primary care during Ramadan. Practice Nursing 31:4, pages 148-154.
Crossref
Crossref
Natalie Darko, Helen Dallosso, Michelle Hadjiconstantinou, Kerry Hulley, Kamlesh Khunti & Melanie Davies. (2020) Qualitative evaluation of A Safer Ramadan, a structured education programme that addresses the safer observance of Ramadan for Muslims with Type 2 diabetes. Diabetes Research and Clinical Practice 160, pages 107979.
Crossref
Crossref
Rajeev Chawla, SV Madhu, BM Makkar, Sujoy Ghosh, Banshi Saboo & Sanjay Kalra. (2020) RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism 24:1, pages 1.
Crossref
Crossref
Rajeev Chawla, S. V. Madhu, B. M. Makkar, Sujoy Ghosh, Banshi Saboo & Sanjay Kalra. (2020) RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. International Journal of Diabetes in Developing Countries 40:S1, pages 1-122.
Crossref
Crossref
Anoop Misra, Hema Gopalan, Ranil Jayawardena, Andrew P. Hills, Mario Soares, Alfredo A. Reza‐Albarrán & Kaushik L. Ramaiya. (2019) Diabetes in developing countries. Journal of Diabetes 11:7, pages 522-539.
Crossref
Crossref
Maryam Rameshrad, Bibi Marjan Razavi, Gordon A. A. Ferns & Hossein Hosseinzadeh. (2019) Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning. DARU Journal of Pharmaceutical Sciences 27:1, pages 341-360.
Crossref
Crossref
Fauzia Rashid & Elamin Abdelgadir. (2019) A systematic review on efficacy and safety of the current hypoglycemic agents in patients with diabetes during Ramadan fasting. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:2, pages 1413-1429.
Crossref
Crossref
Mohammed Bashir, Tarik Elhadd, Hamda Ali, Khaled Baagar, Ibrahim A. Abdel Hakam, Dabia H.S. Al-Mohanadi, Emad Naem, Amina Al Abdulla, Kawsar Mohammed & Abdul-Badie Abou-Samra. (2018) A pilot study using flash continuous glucose monitoring in patients with type-2 diabetes on multiple anti-diabetic agents during Ramadan. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 12:6, pages 965-968.
Crossref
Crossref
Stephen Colagiuri, David Matthews, Lawrence A. Leiter, Siew Pheng Chan, Giorgio Sesti & Michel Marre. (2018) The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Research and Clinical Practice 143, pages 1-14.
Crossref
Crossref
Shaukat Sadikot, K. Jothydev, A.H. Zargar, Jamal Ahmad, S.R. Arvind & Banshi Saboo. (2017) Clinical practice points for diabetes management during RAMADAN fast. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S811-S819.
Crossref
Crossref
Banshi Saboo. (2017) Ramadan fasting in diabetes-exercise in problem-solving. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S713-S714.
Crossref
Crossref
Mohamed Hassanein, Monira Al-Arouj, Osama Hamdy, Wan Mohamad Wan Bebakar, Abdul Jabbar, Abdulrazzaq Al-Madani, Wasim Hanif, Nader Lessan, Abdul Basit, Khaled Tayeb, MAK Omar, Khalifa Abdallah, Abdulaziz Al Twaim, Mehmet Akif Buyukbese, Adel A. El-Sayed & Abdullah Ben-Nakhi. (2017) Diabetes and Ramadan: Practical guidelines. Diabetes Research and Clinical Practice 126, pages 303-316.
Crossref
Crossref
Abdallah M. BeanoMohammad A. ZmailiZaid H. GheithAhmad M. NaserMunther S. MomaniAl-Motassem F. YousefAyman A. Zayed. (2017) Predetermined Anti-Diabetic Drug Regimen Adjustments during Ramadan Fasting: An Observational Study of Safety. Endocrinology and Metabolism 32:2, pages 265.
Crossref
Crossref
S. T. Azar, A. Echtay, W. M. Wan Bebakar, S. Al Araj, A. Berrah, M. Omar, A. Mutha, K. Tornøe, M. S. Kaltoft & N. Shehadeh. (2016)
Efficacy and safety of liraglutide compared to sulphonylurea during
R
amadan in patients with type 2 diabetes (
LIRA‐R
amadan): a randomized trial
. Diabetes, Obesity and Metabolism 18:10, pages 1025-1033.
Crossref
Crossref
Mohamed Khattab, Khalifa Mahmoud & Inass Shaltout. (2016) Effect of Vildagliptin Versus Sulfonylurea in Muslim Patients with Type 2 Diabetes Fasting During Ramadan in Egypt: Results from VIRTUE Study. Diabetes Therapy 7:3, pages 551-560.
Crossref
Crossref
David Morris. (2016) Managing fasting patients with diabetes during Ramadan. Independent Nurse 2016:10, pages 26-29.
Crossref
Crossref
Huai Heng Loh, Anne Yee, Huai Seng Loh, Norlela Sukor & Nor Azmi Kamaruddin. (2016) Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis. Primary Care Diabetes 10:3, pages 210-219.
Crossref
Crossref
Saud Al Sifri & Kashif Rizvi. (2016) Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial Evidence. Diabetes Therapy 7:2, pages 221-240.
Crossref
Crossref
Mussa H. Almalki & Fahad Alshahrani. (2016) Options for Controlling Type 2 Diabetes during Ramadan. Frontiers in Endocrinology 7.
Crossref
Crossref
Ehab Mudher Mikhael. (2016) Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. Journal of Diabetes Research 2016, pages 1-10.
Crossref
Crossref
Shaun Wen Huey Lee, Jun Yang Lee, Christina San San Tan & Chee Piau Wong. (2016) Strategies to Make Ramadan Fasting Safer in Type 2 Diabetics. Medicine 95:2, pages e2457.
Crossref
Crossref
Jean Claude Mbanya, Saud Al-Sifri, Aly Abdel-Rahim & Ilhan Satman. (2015) Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. Diabetes Research and Clinical Practice 109:2, pages 226-232.
Crossref
Crossref
L. J. Gray, J. Dales, E. M. Brady, K. Khunti, W. Hanif & M. J. Davies. (2015) Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism 17:7, pages 639-648.
Crossref
Crossref
Mahmoud Ibrahim, Megahed Abu Al Magd, Firas A Annabi, Samir Assaad-Khalil, Ebtesam M Ba-Essa, Ibtihal Fahdil, Sehnaz Karadeniz, Terry Meriden, Aly A Misha'l, Paolo Pozzilli, Samad Shera, Abraham Thomas, Suhad Bahijri, Jaakko Tuomilehto, Temel Yilmaz & Guillermo E Umpierrez. (2015) Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Research & Care 3:1, pages e000108.
Crossref
Crossref
Gábor Winkler. (2015)
Sulfonylureas in today’s blood glucose lowering therapy.
New data on advantages and potential barriers of an “old” antidiabetic group
. Orvosi Hetilap 156:13, pages 511-515.
Crossref
Crossref
E. M. Brady, M. J. Davies, L. J. Gray, M. A. Saeed, D. Smith, W. Hanif & K. Khunti. (2014) A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Diabetes, Obesity and Metabolism 16:6, pages 527-536.
Crossref
Crossref
S. Halimi & M. Lévy. (2014) Prise en charge des patients diabétiques de type 2 durant le Ramadan : quelle place pour les inhibiteurs de la DPP-4 ?. Médecine des Maladies Métaboliques 8:3, pages 299-305.
Crossref
Crossref
Gábor Winkler. (2014) The use of gliclazide in the mirror of the individualized sulfonylurea therapy. Orvosi Hetilap 155:14, pages 541-548.
Crossref
Crossref
S. El Aziz, S. Skalli, A. Chadli, H. El Ghomari & A. Farouqi. (2014) Diab?te et Ramadan: Mise au point sur les recommandations r?centes. M?decine des Maladies M?taboliques 8:2, pages 221-225.
Crossref
Crossref
Serge Halimi, Marc Levy, Dominique Huet, Stéphane Quéré & Sylvie Dejager. (2013) Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study. Diabetes Therapy 4:2, pages 385-398.
Crossref
Crossref
I. Ahmed. (2013) Ramadan: type 2 diabetes and risk of hypoglycaemia. International Journal of Clinical Practice 67:10, pages 933-934.
Crossref
Crossref
Jamie R. Wood & Janet Silverstein. (2013) Incretins and amylin in pediatric diabetes. Current Opinion in Pediatrics 25:4, pages 502-508.
Crossref
Crossref
Serge Halimi. (2013) Prise en charge du diabète de type 2 : anciens ou nouveaux médicaments, comment choisir ?. La Presse Médicale 42:5, pages 861-870.
Crossref
Crossref